Editor: What To Know
- Stem comes to Glooko having served in a wide range of leadership roles in the life science industry with a focus on the use of real-world data and digital technologies to transform and accelerate clinical trials.
- In her previous role, Stem was founder and CEO of monARC Bionetworks, a health data collection and analytics company aimed at modernizing clinical research by empowering patients to share their real-world data generated from routine care and digital tools so it can be transformed into real-world evidence that accelerates research and improves care.
- “Glooko’s mission to empower people with diabetes to use their data to improve care and contribute real-world data to advance research is completely aligned with my passion to transform research and care using the growing body of real-world data,”.
Komathi Stem has been appointed Chief Operating Officer of Glooko. Stem comes to Glooko having served in a wide range of leadership roles in the life science industry with a focus on the use of real-world data and digital technologies to transform and accelerate clinical trials.
In her new role as COO of Glooko, Komathi Stem will have global responsibility for Glooko product development, clinical research, and customer support.
In her previous role, Stem was founder and CEO of monARC Bionetworks, a health data collection and analytics company aimed at modernizing clinical research by empowering patients to share their real-world data generated from routine care and digital tools so it can be transformed into real-world evidence that accelerates research and improves care.
“Glooko’s mission to empower people with diabetes to use their data to improve care and contribute real-world data to advance research is completely aligned with my passion to transform research and care using the growing body of real-world data,” Stem said. “I’m pleased to be joining the Glooko team as we continue leading the way in turning integrated diabetes data into actionable insights for people with diabetes and their providers.”
Prior to monARC Bionetworks, Komathi Stem has led the transformation of clinical trials via her leadership roles at Science 37, Genentech, AstraZeneca, Amgen and Eli Lilly. She holds a Master of Science degree in biomedical engineering from the University of Virginia.
